w1 Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996;275:128-33.

w2 Davidson M, Ma P, Stein EA, Gotto AM, Raza A, Chitra R, et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002;89:268-75.

w3 Diabetes Atorvastatin Lipid Intervention (DALI) Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001;24:1335-41.

w4 Heinonen TM, Stein E, Weiss SR, McKenney JM, Davidson M, Shurzinske L, Black DM. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Clin Ther 1996;18:853-63.

w5 Hunninghake D, Insull W, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001;158:407-16.

w6 Mullen MJ, Wright D, Donald AE, Thorne S, Thomson H, Deanfield JE. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J Am Coll Cardiol 2000;36:410-6.

w7 Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien P-J, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-82.

w8 Oranje WA, Sels J-PJE, Rondas-Colbers GJWM, lemmens PJMR, Wolffenbuttel BHR. Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients. Clinica Chimica Acta 2001;311:91-4.

w9 Schrott HG, Knapp H, Davila M, Shurzinske L, Black D. Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study. Am Heart J 2000;140:249-52.

w10 Myocardial Ischaemia with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. JAMA 2001:285:1711-8.

w11 Tanaka A, Yamada N, Saito Y, Kawakami M, Ohashi Y, Akanuma Y. A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia. Clinica Chimica Acta 2001;41-7.

w12 Tannous M, Cheung R, Vignini A, Mutus B. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thromb Haemost 1999;82:1390-4.

w13 Vansant G, Mertens A, Muls E. The effect of atorvastatin on postprandial lipaemia in overweight or obese women homozygous for apo E3. Acta Cardiol 2001;56:149-54.

w14 Gentile S, Turco S, Guarino G, Sasso CF, Amodio M, Magliano P, et al. Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. Diabetes Obes Metab 2000;2:355-62.

w15 Paolisso G, Barbagallo M, Petrella G, Ragno E, Barbieri M, Giordano M, et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 2000;150:121-7.

w16 Bevilacqua M, Bettica P, Milani M, Vago T, Rogolino A, Righini V, et al. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol 1997;79:85-7.

w17 Brorholt-Petersen JU, Jensen HK, Raungaard B, Gregersen N,Faergeman O. LDL-receptor gene mutations and the hypocholesterolemic response to statin therapy. Clin Genet 2001;59:397-405.

w18 Dallongeville J, Fruchart JC, Pfister P, Bard JM. Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). J Intern Med 1994;236:95-101.

w19 Eagles CJ, Kendall MJ, Maxwell S. A comparison of the effects of fluvastatin and bezafibrate on exercise metabolism: a placebo-controlled study in healthy normolipidaemic subjects. Br J Clin Pharmacol 1996;41:381-7.

w20 Huhle G, Abletshauser C, Mayer N, Weidinger G, Harenberg J, Heene DL. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res 1999;95:229-343.

w21 Insull W, Black D, Dujovne C, Hosking JD, Hunninghake D, Keilson L, et al. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia. Arch Intern Med 1994;154:2449-55.

w22 John S, Schlaich M, Langenfeld M, Weihprecht H, Schmitz G, Weidinger G, Schmieder RE. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients. Circulation 1998;98:211-6.

w23 Jokubaitis A, Knopp RH, Frohlich J. Efficacy and safety of fluvastatin in hyperlipidaemic patients with non-insulin-dependent diabetes mellitus. J Intern Med 1994;236:103-7.

w24 Knopp RH, Frohlich J, Jokubaitis LA, Dawson K, Broyles FE, Gomez-Coronado D. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia. Am J Med 1994;96:6A-9A.

w25 Leonhardt W, Kurktschiev T, Meissner D, Lattke P, Abletshauser C, Weidinger G, et al. Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metal. Eur J Clin Pharmacol 1997;53:65-9.

w26 Lye M, Valacio R, Reckless JPD, Ghosh AK, Findlay IN, Ghosh MK, et al. Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin. Coronary Artery Dis 1998;9:583-90.

w27 Peters TK, Mehra M, Muratti EN. Efficacy and safety of fluvastatin in hypertensive patients. Am J Hypertens 1993;6:340S-5S.

w28 Porsch-Özcűrűmez M, Hardt PD, Schnell-Kretschmer H, von Bergmann K, Darui C, Nonhoff, et al. Effects of fluvastatin on biliary lipids in subjects with an elevated cholesterol saturation index. Eur J Clin Pharmacol 2001;56:873-9.

w29 Romano M, Mezzetti A, Marulli C, Ciabattoni G, Febo F, Di Lenno S, et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxid. J Investig Med 2000;48:183-9.

w30 Broyles FE, Walden CE, Hunninghake DB, Hill-Williams D, Knopp RH. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia. Am J Cardiol 1995;76:129A-135A.

w31 Jacobson TA, Jokubaitis LA, Amorosa LF. Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy. Am J Med 1994;96(suppl6A):6A-64S.

w33 Ding PY-A, Sheu WH-H, Hu C-A, Pei D. Efficacy and safety of fluvastatin in patients with non-insulin dependent diabetes mellitus and hypercholesterolemia. Acta Cardiol Sin 1997;13:138-44.

w34 Haak E, Abletshauser C, Weber S, Goedicke C, Martin N, Hermanns N, et al. Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia. Atherosclerosis 2001;155:395-401.

w35 Visseren FLJ, Bouter PK, van Loon BJP, Erkelens WD. Treatment of dyslipidaemia with fluvastatin in patients with type 2 diabetes mellitus. Clin Drug Invest 2001;21:671-8.

w36 Granero R, Linfa-Homes G, Isaacura-López CI, Goyo A, y Adiel Sira AF-F . Clinical trial with sodium fluvastatin in patients with hypercholesterolemia associated with mild and moderate essential arterial hypertension. [Spanish] Invest Clin 1997;38:63-72.

w37 Superko HR, Krauss RM, DiRicco C. Effect of fluvastatin on low-density lipoprotein peak particle diameter. Am J Cardiol 1997;80:78-81.

w38 Tan KCB, Janus ED, Lam KSL. Effects of fluvastatin on prothrombotic and fibrinolytic factors in type 2 diabetes mellitus. Am J Cardiol 1999;84:934-7.

w39 Asymptomatic Carotid Artery Progression Study (ACAPS) Research Grup. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation 1994;90:1679-87.

w40 Bradford RH, Shear CL, Chremos AN, Dujovne CA, Franklin FA, Grillo RB, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up. Am J Cardiol 1994;74;667-73.

w41 Davidson MH, Toth P, Weiss S, KcKenney J, Hunninghake D, Isaacsohn J, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 2001;24:467-74.

w42 Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med 1988;318:81-6.

w43 Golper TA, Illingworth R, Morris CD, Bennett WM. Lovastatin in the treatment of multifactorial hyperlipidemia associated with proteinuria. Am J Kidney Dis 1989;13:312-20.

w44 Grundy SM, Vega GL. Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J Lipid Res 1985;26:1464-75.

w45 Havel RJ, Hunninghake DB, Illingworth DR, Lees RS, Stein EA, Tobert JA, et al. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. Ann Intern Med 1987;107:609-15.

w46 Hoeg JM, Maher MB, Zech LA, Bailey KR, Gregg RE, Lackner KJ, et al. Effectiveness of mevinolin on plasma lipoprotein concentrations in type Ii hyperlipoproteinemia. Am J Cardiol 1986;57:933-9.

w47 Jacobson TA, Jokubaitis LA. Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy. Am J Med 1994;96:64S-8S.

w48 Lovastatin Study Group II. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. JAMA 1986;256:2829-34.

w49 Palomäki A, Malminiemi K, Metsä-Ketelä T. Enhanced oxidizability of ubiquinol and a -tocopherol during lovastatin treatment. FEBS Lett 1997;410:254-8.

w50 Santanello NC, Barber BL, Applegate WB, Elam J, Curtis C, Hunninghake DB, et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) pilot study. J Am Geriatr Soc 1997;45:8-14.

w51 Weder AB, Serr C, Torretti BA, Bassett DR, Sweifler AJ. Effects of lovastatin treatment on red blood cell and platelet cation transport. Hypertension 1991;17:203-9.

w52 Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol 1994;34:989-96.

w53 Aguilar-Salinas CA, Barrett PHR, Pulai J, Zhu XL, Schonfeld G. A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Arterioscler Thromb Vasc Biol 1997;17:72-82.

w54 Guillen MA, Kornhauser C, Samaniego V, de Tejada AL, Sanchez H. Once-daily pravastatin compared with dietary advice in patients with borderline and moderate primary hypercholesterolemia. Curr Ther Res 1995;56:305-17.

w55 Ritter JM, Severt P, Brassfield T. Pravastatin once daily in hypercholesterolaemia: a UK study. J Clin Pharm Ther 1993;18:421-6.

w56 Meyers DG, Bays HE, Weiner BH, Stoltz R. Short-term efficacy and safety of pravastatin in hypercholesterolemic women. J Womens Health 1995;4:357-65.

w57 Frederiksen SM, Larsen ML, Oxenbøll IB, Pindborg T, Haghfelt T. Treatment of primary hypercholesterolaemia with pravastatin - a placebo-controlled study. [Danish] Ugeskr Læger 1993;155:2794-9.

w58 Palazzuoli V, Mondillo S, Faglia S, D’Aprile N, Mangiacotti L. Comparison of pravastatin and diet in the treatment of hypercholesterolemia. [Italian] Cliica Terapeutica 1995;146:587-93.

w59 Avellone G, di Garbo V, Cordova R, Raneli G, de Simone R, Bompiani G. Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIB hyperlipoproteinemia. Curr Ther Res 1994;55:1335-44.

w60 Ferrari P, Weidmann P, Riesen WF, Martius F, Luban S, Pasotti E, et al. Pravastatin in the treatment of primary hypercholesterolemia: A Swiss multicenter study. [German] Journal Suisse de Medecine 1993;123:1736-41.

w61 Knopp RH, Illingworth DR, Stein EA, Ginsberg HN, Broyles FE, Behounek BD. Effect of pravastatin in the treatment of patients with type III hyperlipoproteinemia. Am J Ther 1996;3:755-62.

w62 Fogari R, Tettamanti F, Zoppi A, Malamani GD, Lazzari P, Agosta G, et al. Effects of chronic treatment with pravastatin in patients with mild hypercholesterolemia and associated cardiovascular risk factors. Curr Ther Res 1992;51:896-905.

w63 Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels. JAMA 2001;286:64-70.

w64 Bak AAA, Huizer J, Leijten PA, Rila H, Grobbee DE. Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle-aged men free from cardiovascular disease. J Intern Med 1998;244:371-8.

w65 Beigel Y, Brook G, Eisenberg S, Fainaru M, Harats D, Levy Y, et al. Efficacy and safety of pravastatin once daily in primary moderate hypercholesterolemia: the Israeli experience. Isr J Med Sci1993;29:272-7.

w66 Betteridge DJ, Bhatnager D, Bing RF, Durrington PN, Evans GR, Flax H, et al. Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. BMJ 1992;304:1335-8.

w67 Bhatnagar D, Durrington PN, Kumar S, Mackness MI, Dean J, Boulton AJM. Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes 1995;44:460-5.

w68 Blann AD, Gurney D, Hughes E, Buggins P, Silverman SH, Lip GYH. Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease. Am J Cardiol 2001;88:89-92.

w69 Chan P, Tomlinson B, Lee C-B, Pan W-H, Lee Y-S. Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects. Hypertension 1996;28:647-51.

w70 Cobbaert C, Sergeant P, Szécsi J, Kesteloot H. Time course of serum Lp(a) in men after coronary artery bypass grafting. Acta Cardiol 1992;47:529-42.

w71 Contacos C, Barter PJ, Sullivn DR. Effect of pravastatin and w -3 fatty acids on plasma lipids and lipoproteins in patients with combined hypercholesterolemia. Arterioscler Thromb 1993;13:1755-62.

w72 Davidson MH, Testolin LM, Maki KC, von Duvillard S, Drennan KB. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med 1997;157:1186-92.

w73 Den Hartog FR, Van Kalmthout PM, Van Loenhout TT, Schaafsma HJ, Verheugt FWA. Pravastatin in acute ischaemic syndromes: results of a randomised placebo-controlled trial. Int J Clin Pract 2001;55:300-4.

w74 Dupuis J, Tardif J-C, Cernacek P, Théroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. Circulation 1999;99:3227-33.

w75 Galvan AQ, Natali A, Baldi S, Frascerra S, Sampietro T, Galetta F, et al. Effect of a reduced-fat diet with or without pravastatin on glucose tolerance and insulin sensitivity in patients with primary hypercholesterolemia. J Cardiovasc Pharmacol 1996;28:595-602.

w76 Glasser SP, DiBianco R, Efforn BA, Faas F, Germino FW, Shane LE, et al. The efficacy and safety of pravastatin in patients aged 60 to 85 years with low-density lipoprotein cholesterol >160 mg/dl. Am J Cardiol 1996;77:83-5.

w77 Hunninghake DB, Knopp RH, Schonfeld G, Goldberg AC, Brown WV, Schaefer EJ, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 1990;85:81-9.

w78 Hunninghake DB, Mellies MJ, Goldberg AC, Kuo PT, Kostis JB, Schrott HG, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 1990;85:219-27.

w79 Imai Y, Suzuki H, Saito T, Tsui I, Abe K, Saruta T. The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Clin Exp Hypertens 1999;21:1345-55.

w80 Jacobson TA, Chin MM, Curry CL, Miller V, Papademetriou V, Schlant RC, LaRosa JC. Efficacy and safety of pravastatin in African Americans with primary hypercholesterolemia. Arch Intern Med 1995;155:1900-6.

w81 Janatuinen T, Laaksonen R, Vesalainen R, Raitakari O, Lehtimäki T, Nuutila P, et al. Effect of lipid-lowering therapy with pravastatin on myocardial blood flow in young mildly hypercholesterolemic adults. J Cardiovasc Pharmacol 2001;38:561-8.

w82 Jones PH, Farmer JA, Cressman MD, McKenney JM, Wright JT, Proctor JD, et al. Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study. Clin Cardiol 1991;14146-51.

w83 Jukema JW, Bruschke AVG, van Boven AJ, Reiber JHC, Bal ET, Zwinderman AH, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Study (REGRESS). Circulation 1995;91:2528-40.

w85 Kesteloot H, Claeys G, Blanckaert N, Lesaffre E. Time course of serum lipids and apoliporoteins after acute myocardial infarction: modification by pravastatin. Acta Cardiologica 1997;LII:107-16.

w86 Kool M, Lustermans F, Kragten H, Struijker Boudier H, Hoeks A, Reneman R, et al. Does lowering cholesterol levels influence functional properties of large arteries? Eur J Clin Pharmacol 1995;48:217-23.

w87 Krempf M, Berthezène F, Wemeau JL, Moinade S, Desriac I, Amelineau E, et al. Efficacy of low-dose pravastatin in patients with mild hyperlipidemia associated with type II diabetes mellitus. Diabet Metab 1997;23:131-6.

w88 Le Quan Sang K-H, Levenson J, Megnien J-L, Simon A, Devynck M-A. Platelet cytosolilc Ca^2a and membrane dynamics in patients with primary hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:759-64.

w89 Lijnen P, Celis H, Desager JP, Fagard R. Changes in plasma lipids, lipoproteins and apolipoproteins in hypercholesterolaemic patients treated with pravastatin. J Hum Hypertens 1995;9:557-64.

w90 Linden NH, de Rooy FWM, Jansen H, van Blankenstein M. Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia. Gut 1990;31:348-50.

w91 Megnien JL, Simon A, Andriani A, Segond P, Jeannin S, Levenson J. Cholesterol lowering therapy inhibits the low-flow mediated vasoconstriction of the brachial artery in hypercholesterolaemic subjects. Br J Clin Pharmacol 1996;42:187-93.

w92 Mercuri M, Bond G, Sirtori CR, Veglia F, Crepaldi G, Feruglio FS, et al. Pravastatin reduces carotid intima-media thickness progressionin an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996;101:627-34.

w93 Morris R, Robinson G, Tilyard M, Gurr E. Pravastatin and risk factor modification in patients with moderate primary hypercholesterolaemia. N Z Med J 1996;109:319-22.

w94 Mostaza JM, Gomez MV, Gallardo F, Salazar ML, Martín-Jadraque R, Plaza-Celemín, et al. Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels. J Am Coll Cardiol 2000;35:76-82.

w95 Mulder HJGH, Schalij MJ, Kauer B, Visser RF, van Dijkman PRM, Jukema JW, et al. Pravastatin and endothelium dependent vasomotion after coronary angioplasty: the PREFACE trial. Heart 2001;86:533-9.

w96 Nakamura Y, Yamaoka O, Uchida K, Morigami N, Sugimoto Y, Fujita T, et al. Pravastatin reduces restenosis after coronary angioplasty of high grade stenotic lesions: results of SHIPS (SHIga Pravastatin Study). Cardiovasc Drugs Ther 1996;10:475-83.

w97 Newby DE, Witherow FN, Wright RA, Bloomfield P, Ludlam CA, Boon NA, et al. Hypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo. Heart 2002;87:48-53.

w98 O’Callaghan CJ, Krum H, Conway EL, Lam W, Skiba M, Howes LG, et al. Short term effects of pravastatin on blood pressure in hypercholesterolemic hypertensive patients. Blood Pres 1994;3:404-6.

w99 Pravastatin Multicenter Study Group II. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolmia. Arch Intern Med 1993;153:1321-9.

w100 PREDICT (Prévention des Restenoses par Elisor après Dilatation Coronaire Transluminale) Trial Investigators. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. J Am Coll Cardiol 1997;30:863-90.

w101 Pravastatin Multinational Study Group (PMSG) for Cardiac Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993;72:1031-7.

w102 Rubenfire M, Maciejko JJ, Blevins RD, Orringer C, Kobylak L, Rosman H, et al. The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. Arch Intern Med 1991;151:2234-40.

w103 Rustemeijer C, Schouten JA, Janssens ENW, Spooren PFMJ, van Doormaal JJ. Pravastatin in diabetes-associated hypercholesterolemia. Acta Diabetol 1997;34:294-300.

w104 Saito Y, Goto Y, Nakaya N, Hata Y, Homma Y, Naito C, et al. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. Atherosclerosis 1988;72:205-11.

w105 Santinga JT, Rosman HS, Rubenfire M, Maciejko JJ, Kobylak L, McGovern ME, et al. Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia. Am J Med 1994;96:509-15.

w106 Santos RD, Sposito AC, Ventura LI, Cesar LAM, Ramires JAF, Maranhão RC. Effect of pravastatin on plasma removal of a chylomicron-like emulsion in men with coronary artery disease. Am J Cardiol 2000;85:1163-6.

w107 Saxenhoger H, Weidmann P, Riesen WF, Beretta-Piccoli C, Fragiacomo C, Wunderlin R, et al. Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II. Eur J Clin Pharmacol 1990;39:101-5.

w108 Smit JWA, van Erpecum KJ, Renooij W, Stolk MF, Edgar P, Doornewaard H, et al. The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease. Hepatology 1995;21:1523-9.

w109 Solheim S, Seljeflot I, Arnesen H, Eritsland J, Eikvar L. Reduced levels of TNFa in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks. Atherosclerosis 2001;157:411-15.

w110 Straznicky NE, Howes LG, Lam W, Louis WJ. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol 1995;75:582-6.

w111 Vanhanen HT, Miettinen TA. Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination. Atherosclerosis 1995;115:135-46.

w112 Vega GI, Krauss RM, Grundy SM. Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J Intern Med 1990;227:81-94.

w113 Wiklund O, Angelin B, Fager G, Eriksson M, Olofsson S-O, Berglund I, et al. Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. J Intern Med 1990;228:241-7.

w115 Zhang A, Vertommen J, Van Gaal L, De Leeuw I. Effects of pravastatin on lipid levels, in vitro oxidizability of non-HDL lipoproteins and microalbuminuria in IDDM patients. Diabetes Res Clin Pract 1995;29:189-4.

w116 Cutler N, Sramek J, Veroff A, Block G, Stauffer L, Lines C. Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia. Br J Clin Pharmacol 1995;39:333-6.

w117 Dobs AS, Miller S, Neri G, Weiss S, Tate AC, Shapiro DR, et al. Effects of simvastatin and pravastatin on gonadal function in male hypercholesterolemic patients. Metabolism 2000;49:115-21.

w118 Eckernäs S-A, Roos B-E, Kvidal P, Eriksson L-O, Block GA, Neafus RP, et al. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Br J Clin Pharmac 1993;35:284-9.

w119 Ghirlanda G, Oradei A, Manto A, Lippa S, Uccioli L, Caputo S, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993;33:226-9.

w120 Stein JH, Carlsson CM, Papcke-benson K, Aeschlimann SE, Bodemer A, Carnes M, et al. The effects of lipid-lowering and antioxidant vitamin therapies on flow-mediated vasocilation of the brachial artery in older adults with hypercholesterolemia. J Am Coll Cardiol 2001;38:1806-13.

w121 Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 2001;88:504-8.

w122 Betteridge DJ. International multicentre comparison of cerivastatin with placebo and simvastatin for the treatment of patients with primary hypercholesterolaemia. Int J Clin Pract 1999;53:243-50.

w123 Broijersen A, Mats E, Leijd B, Angelin B, Hjemdahl P. No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997;17:273-8.

w124 Valerio G, Vigna GB, Vitale E, Romagnoni F, Fellin R. Low-dose simvastatin treatment in patients with moderate-grade familial hypercholesterolemia. Curr Ther Res 1990;48:701-6.

w125 Lepre F, Nestel P, Clifton P, Lloyd B, Morgan T. Low-dose simvastatin in the treatment of mild to moderate hypercholesterolaemia. Clin Drug Invest 1997;13:237-41.

w126 Walker JF, Pingeon RA, Shapiro DA. Efficacy and tolerability of simvastatin (epistatin) in the elderly. Drug Invest 1990;2(Suppl2):53-6.

w127 Johansson J. Low-dose combination therapy with colestipol and simvastatin in patienrs with moderate to severe hypercholesterolaemia. Nutr Metab Cardiovasc Dis 1995;5:39-44.

w128 Farish E, MacDonald NJ, Barnes JF, Stark S, Reid JL. A double-blind twelve-week placebo-controlled study to assess the efficacy of simvastatin in the treatment of hypercholesterolaemia in hypertensive patients. J Drug Dev 1990;3 (Suppl1):259-63.

w129 Berioli S, Bentivoglio M, Conti R, Osanna RA, Savino A, Zollino L, Corea L. Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide. [Italian] Cardiologia 1990;35:335-40.

w130 Bach LA, Wirth A, O’Brien RC, Jerums G, Cooper ME. Cholesterol lowering effects of simvastatin in patients with non-insulin dependent diabetes mellitus. Diab Nutr Metab 1991;4:123-8.

w131 Kuhn P, Darioli R, Bovet P, Bercher L, Brunner HR. Dose-dependent lipid-lowering effects of simvastatin (MK-733) in the elderly. Curr Ther Res 1989;46:381-9.

w132 Resta F, Colacicco AM, di Tommaso M, Vespertino E, Venezia A, Auteri P, Capurso A. The effect of low-dose simvastatin on serum lipid, lipoprotein, and apolipoprotein concentrations in primary moderate hypercholesterolemia. Curr Ther Res 1993;54:508-18.

w133 Capruso A, Resta F, Bertolini S, Masturzo P, Feruglio FS, Cattin L, et al. Lipid control with low-dosage simvastatin in patients with moderate hypercholesterolemia. An Italian multicentre double-blind placebo-controlled study. Eur Heart J 1992;13:11-6.

w134 Chan P, Huang T-Y, Tomlinson B, Lee C, Lee Y-S. Short-term safety and efficacy of low-dose simvastatin in elderly patients with hypertensive hypercholesterolemia and fasting hyperinsulinemia. J Clin Pharmacol 1997;37:496-501.

w135 de Divitiis M, Rubba P, Di Somma S, Liguori V, Galderisi M, Montefusco S, et al. Effects of short-term reduction in serum cholesterol with simvastatin in patients with stable angina pectoris and mild to moderate hypercholesterolemia. Am J Cardiol 1996;78:763-8.

w136 Dobs AS, Schrott H, Davidson MH, Bays H, Stein EA, Kush D, et al. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism 2000;49:1234-8.

w137 Haffner S, Orchard T, Stein E, Schmidt D, LaBelle P. Effect of simvastatin on Lp(a) concentrations. Clin Cardiol 1995;18:261-7.

w138 Hwu CM, Kwok CF, Chen HS, Shiht KC, Lee SH, Hsiaot LC, et al. Lack of effect of simvastatin in insulin sensitivity in type 2 diabetic patients with hypercholesterolaemia: results from a double-blind, randomized, placebo-controlled crossover study. Diabet Med 1999;16:749-54.

w139 Jacobs H, Van de Werf F, Lesaffre E, De Geest H, Collen D. A randomized placebo controlled trial on the effects of simvastatin, a HMG-CoA reductase inhibitor, on blood lipids and fibrinolytic parameters. Acta Clinica Belgica 1992;47:82-9.

w140 Keech A, Collins R, MacMahon S, Armitage J, Lawson A, Wallendszus K, et al. Three-year follow-up of the Oxford Cholesterol Study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study. Eur Heart J 1994;15:255-69.

w141 Kjaer K, Hangaard J, Petersen NE, Hagen C. Effect of simvastatin in patients with type I (insulin-dependent) diabetes mellitus and hypercholesterolemia. Acta Endocrinol 1992;126:229-32.

w142 Knapp HH, Schrott H, Ma P, Knopp R, Chin B, Gaziano M, Donovan JM, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001;110:352-60.

w143 Lagrost L, Athias A, Lemort N, Richard J-L, Desrumaux C, Châtenet-Duchêne L, et al. Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin. Atherosclerosis 1999;143:415-25.

w144 MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344:633-8.

w145 MacMahon M, Kirkpatrick C, Cummings CE, Clayton A, Robinson PJ, Tomiak RHH, et al. A pilot study with simvastatin and folic acid/vitamin B₁₂ in preparation for the study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH). Nutr Metabl Cardiovasc Dis 2000;10:195-203.

w146 Mansourati J, Newman L, Roman SH, Travis A, Rafey M, Phillips RA. Lipid lowering does not improve endothelial function in subjects with poorly controlled diabetes. Diabetes Care 2001;24:2152-3.

w147 McDowell IFW, Smye M, Trinick T, Shortt JA, Archibald MP, Trimble ER, et al. Simvastatin in severe hypercholesterolaemia: a placebo controlled trial. Br J Clin Pharmac 1991;31:340-3.

w148 Morgan T, Anderson A, McDonald P, Hopper J, Macaskill G. Simvastatin in the treatment of hypercholesterolaemia in patients with essential hypertension. J Hypertens 1990;8:S25-32.

w149 Nielsen S, Schmitz O, Møller N, Pørksen N, Klausen IC, Alberti KGMM, Mogensen CE. Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1993;36:1079-86.

w150 Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, Giammarresi A, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type Iia hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:247-51.

w151 O’Driscoll G, Green D, Taylor R. Simvastatin, an HMG-Coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997;95:1126-31.

w152 Paolisso G, Sgambato S, De Riu S, Verza M, Varricchio M, D’Onofrio F. Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics. Eur J Clin Pharmacol 1991;40:27-31.

w153 Saito Y, Yoshida S, Nakaya N, Hata Y, Goto Y. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. Arterioscler Thromb 1991;11:816-26.

w154 Sardo MA, Castaldo M, Cinquegrani M, Nonaiuto M, Maesano A, Schepis, et al. Effects of simvastatin treatment on sICAM-1 and sE-selectin levels in hypercholesterolemic patients. Atherosclerosis 2001;155:143-7.

w155 Sbarouni E, Kyriakides ZS, Kremastinos TH. The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. J Am Coll Cardiol 1998;32:1244-50.

w156 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.

w157 Shige H, Dart A, Nestel P. Simvastatin improves arterial compliance in the lower limb but not in the aorta. Atherosclerosis 2001;155:245-50.

w158 Stein E, Plotkin D, Bays H, Davidson M, Dujovne C, Korenman S, et al. Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. Am J Cardiol 2000;86:406-11.

w159 Stewart MW, Dyer RG, Alberti KGMM, Laker MF. The effects of lipid lowering drugs on metabolic control and lipoprotein compostion in type 2 diabetic patients with mild hyperlipidaemia. Diabet Med 1995;12:250-7.

w160 Thomas ME, Harris KPG, Ramaswamy C, Hattersley JM, Wheeler DC, Varghese Z, et al. Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 1993;44:1124-9.

w161 Tonolo G, Ciccarese M, Brizzi P, Puddu L, Secchi G, Pierangela C, et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997;20:1891-5.

w162 Tuomilehto J, Guimaraes AC, Kettner H, Lithell H, Pitkänen M, Sailer D, et al. Dose-response of simvastatin in primary hypercholesterolemia. J Cardiovasc Pharmacol 1994;24:941-9.

w163 Vita JA, Yeung AC, Winniford M, Hodgson JM, Treasure CB, Kelin JL, et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 2000;102:846-51.

w164 Watts GF, Naoumova RP, Kelly JM, Riches FM, Croft KD, Thompson GR. Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects. Am J Physiol 1997;273:E462-70.

w165 Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58.

w166 Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). JAMA 1998;279:1615-22.

w167 Downs JR, Clearfield M, Tyroler HA, Whitney EJ, Kruyer W, Langendorfer A, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): Additional prespectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001;87:1074-9.

w168 PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.

w169 West of Scotland Coronary Prevention Study (WOSCOPS) Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995;333:1301-7.

w170 Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Belder R, Park J, et al. Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995;92:1758-64.

w171 Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995;92:2419-25.

w172 Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Substudy. Circulation2002;106:1690-5.

w173 Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention: the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Curr Med Res Opin 2002;18:220-8.

w174 Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. JAMA 2002;287:3215-22.

w175 Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: final results of the Fluvastatin Angiographic Restenosis (FLARE) trial. Eur Heart J 1999;20:58-69.

w176 Herd JA. The Lipoproteing and Coronary Atherosclerosis Study (LCAS): lipid and metabolic factors related to atheroma and clinical events. Am J Med 1998;104:42S-49S.

w177 Herd JA, Ballantyne CM, Farmer JA, Ferguson III JJ, Jones PH, West MS, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997;80:278-86.

w180 Riegger G, Abletshauser C, Ludwig M, Schwandt P, Widimsky J, Weidinger G, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999;144:263-70.

w179 The Post Coronary Artery Bypass Graft (Post CABG) Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-62.

w180 Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial (CCAIT). Circulation 1994;89:959-68.

w181 Sahni R, Maniet AR, Voci G, Banka VS. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J 1991;121:1600-8.

w182 Lovastatin Restenosis Trial (LRT) Study Group. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994;331:1331-7.

w183 The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.

w184 White HD, Simes RJ, AndersonNE, Graeme MB, Hankey GJ, Watson JDG, et al. Pravastatin therapy and the risk of stroke. N Engl J Med 2000;343:317-26.

w185 Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, et al. Safety and tolerability of pravastatin in long-term clinical trials. Circulation2002;105:2341-6.

w186 Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: the Cholesterol and Recurrent Events (CARE) Trial. N Engl J Med 1996;335:1001-9.

w187 Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, et al. Reduction of stroke events with pravastatin. Circulation 2001;103:387-92.

w188 The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA 2002;288:2998-3007.

w189 Furberg CD, Pitt B, Byington RP, Park J, McGovern ME. Reduction in coronary events during treatment with pravastatin: the Pravastatin Limitation of Atherosclerosis [PLAC I] and Pravastatin, Lipids and Atherosclerosis [PLAC II] studies. Am J Cardiol 1995;76:60C-63C.

w190 Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia: Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002;39:610-6.

w191 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.

w192 Collins R, Armitage J, Parish S, Sleight P, Peto R for the MRC/BJF Heart Protection Study Collaborative Group. Correspondence: authors’ reply. Lancet 2002;360:1783.

w193 Teo KK, Burton JR, Buller CE, Plante S, Catellier D, Tymchak W, et al. Long-term effects of cholesterol lowering and angiotensin-converting ensyme inhibition on coronary atherosclerosis: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000;102:1748-54.

w194 Bestehorn H-P, Rensing UFE, Roskamm H, Betz P, Benesch L, Schemeitat K, et al. The effect of simvastatin on progression of coronary artery disease: the Multicenter Coronary Intervention Study (CIS). Eur Heart J 1997;18:226-343.

w195 Brown BG, Zhao X-Q, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant viramins, or the combination for the prevention of coronary disease: the HDL Atherosclerosis Treatment Study (HATS). N Engl J Med 2001;345:1583-92.

w196 St Mary’s, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Cardiovascular outcomes in type 2 diabetes. Diabetes Care 1998;21:641-8.

w197 Lopid Coronary Angiography Trial (LOCAT) Study Group. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coroanary bypass surgery in men with low levels of HDL cholesterol. Circulation 1997;96:2137-43.

w198 Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002;325:1139-41.

w199 Meade T. Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER) trial of bezafibrate in men with lower extremity arterial disease. Curr Control Trials Cardiovasc Med 2001;2:195-204.

w200 Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenobibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study (DAIS), a randomised study. Lancet 2001;357:905-10.

w201 Lindenstrøm E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen city heart study. BMJ 1994;309:11-5.

w202 Eastern Stroke and Coronary Heart Disease Collaborative Research Group. Blood pressure, cholesterol, and stroke in eastern Asia. Lancet 1998;352:1801-7.

w203 Katsuhiko Y, Reed DM, MacLean CJ. Serum cholesterol and hemorrhagic stroke in the Honolulu heart program. Stroke 1989;20:1460-5.

w204 Leppälä JM, Virtamo J, Fogelholm R, Albanes D, Heinonen OP. Difference risk factors for different stroke subtypes. Association of blood pressure, cholesterol and antioxidants. Stroke 1999;30:2535-40.

w205 Neaton JD, Blackburn H, Jacobs D et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 1992;152:1490–500.

w206 Hart CL, Hole DJ, Davey Smith G. The relation between cholesterol and haemorrhagic or ischaemic stroke in the Renfrew/Paisley study. J Epidemiol Community Health 2000;54:874-5.

w207 Okumura K, Iseki K, Wakugami K, Kimura Y, Muratani H, Ikemiya Y, et al. Low serum cholesterol as a risk factor for hemorrhagic stroke in men. Jpn Circ J 1999;63:53-8.

w208 Suh I, Jee SH, Kim HC, Nam CM, Kim IS, Appel LJ. Low serum cholesterol and haemorrhagic stroke in men: Korea Medical Insurance Corporation Study. Lancet 2001;357:922-5.

w209 Iribarren C, Jacobs DR, Sadler M, Claxton AJ, Sidney S. Low total serum cholesterol and intracerebral hemorrhagic stroke: is the association confined to elderly men? Stroke 1996;27:1993-8.

w210 Lauria G, Gentile M, Fassetta G, Casetta I, Agnoli F, Andreotta G, et al. Incidence and prognosis of stroke in the Belluno Province, Italy. Stroke 1995;26:1787-93.

w211 Giroud M, Milan C, Beuriat P, Gras P, Essayagh E, Arveux P, et al. Incidence and survival rates during a two-year period of intracerebral and subarachnoid haemorrhages, cortical infarcts, lacunes and transient ischaemic attacks. The Stroke Registry of Dijon: 1985-9. Int J Epidemiol 1991;20:892-9.

w212 Vemmos KN, Bots ML, Tsibouris PK, Zis VP, Grobbee DE, Stranjalis GS, et al. Stroke incidence and case fatality in Southern Greece. Stroke 1998;30:363-70.

w213 Jøgensen HS, Plesner A, Hübbe P, Larsen K. Marked increase of stroke incidence in men between 1972 and 1990 in Frederiksberg, Denmark. Stroke 1992;23:1701-4.

w214 Ellakjær H, Holmen J, Indredavik B, Terent A. Epidemiology of stroke in Innherred, Norway, 1994-1996. Stroke 1997;28:2180-4.

w215 Jerntorp P, Berglund G. Stroke registry in Malmö, Sweden. Stroke 1992;23:357-61.

w216 D’Alessandro G, Di Giovanni M, Roveyaz L, Iannizzi L, Compagnoni MP, Blanc S, et al. Incidence and prognosis of stroke in the Valle d’Aosta, Italy. Stroke 1992;23:1712-5.

w217 Bogousslavsky JM van Melle G, Regli F. The Lausanne stroke registry: analysis of 1,000 consecutive patients with first stroke. Stroke 1988;19:1083-92.